Related Experiment Video

Updated: May 10, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide

Christiane M Koller1, Young Kim, Ingo G H Schmidt-Wolf

  • 1Department of Internal Medicine III, Center for Integrated Oncology, University Hospital Bonn, 53105 Bonn, Germany. Ingo.Schmidt-Wolf@ukb.uni-bonn.de

Anticancer Research
|June 11, 2013
PubMed
Abstract

Insights

This study shows that combining wingless-related integration site (WNT) inhibitors with a bi-functional peptide synergistically reduces renal cancer cell vitality. This combination may offer new, less toxic treatment options for advanced renal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Advanced renal cancer presents a significant therapeutic challenge with a poor prognosis.
  • Wingless-related integration site (WNT) inhibitors and bi-functional peptides have demonstrated individual efficacy in cancer treatment.
  • Understanding combination therapies is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the synergistic effect of combining WNT inhibitors with a novel bi-functional peptide in renal cancer treatment.
  • To evaluate the potential of this combination therapy to enhance anti-cancer activity while minimizing toxicity.

Main Methods:

  • A bi-functional peptide comprising a target domain (LTVSPWY) and a lytic domain (KLAKLAK)2 was synthesized.
  • Three WNT inhibitors (Ethacrinic acid, ciclopirox olamine, piroctone olamine) were combined with the bi-functional peptide.
  • The efficacy of these combinations was assessed on three renal cancer cell lines using the MTT assay.

Main Results:

  • A significant synergistic effect was observed between WNT inhibitors and the bi-functional peptide.
  • Cancer cell vitality was markedly reduced (p<0.05) in the combination treatment groups.
  • Healthy cells remained largely unaffected, indicating a degree of selectivity.

Conclusions:

  • The combination of WNT inhibitors and the bi-functional peptide demonstrates promising synergistic anti-cancer activity.
  • This combination therapy holds potential for developing novel treatment strategies for advanced renal cancer.
  • Reduced agent dosage in combination therapy may lead to decreased toxic side-effects, improving patient tolerance.
Keywords:
Renal cancerWNT inhibitorsbi-functional peptidetargeted therapy

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...